JP2024514826A5 - - Google Patents

Info

Publication number
JP2024514826A5
JP2024514826A5 JP2023561742A JP2023561742A JP2024514826A5 JP 2024514826 A5 JP2024514826 A5 JP 2024514826A5 JP 2023561742 A JP2023561742 A JP 2023561742A JP 2023561742 A JP2023561742 A JP 2023561742A JP 2024514826 A5 JP2024514826 A5 JP 2024514826A5
Authority
JP
Japan
Prior art keywords
methyl
alkyl
chloro
fluorophenyl
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023561742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514826A (ja
JP7869809B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/053367 external-priority patent/WO2022219495A1/en
Publication of JP2024514826A publication Critical patent/JP2024514826A/ja
Publication of JP2024514826A5 publication Critical patent/JP2024514826A5/ja
Application granted granted Critical
Publication of JP7869809B2 publication Critical patent/JP7869809B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023561742A 2021-04-12 2022-04-11 肥満の治療のためのglp1受容体の活性化因子としての2-((4-((s)-2-(4-クロロ-2-フルオロフェニル)-2-メチルベンゾ[d][1,3]ジオキソール-4-イル)ピペリジン-1-イル)メチル)-1-(((s)-オキセタン-2-イル)メチル)-1h-イミダゾール誘導体 Active JP7869809B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173592P 2021-04-12 2021-04-12
US63/173,592 2021-04-12
US202263308843P 2022-02-10 2022-02-10
US63/308,843 2022-02-10
US202263323401P 2022-03-24 2022-03-24
US63/323,401 2022-03-24
PCT/IB2022/053367 WO2022219495A1 (en) 2021-04-12 2022-04-11 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity

Publications (3)

Publication Number Publication Date
JP2024514826A JP2024514826A (ja) 2024-04-03
JP2024514826A5 true JP2024514826A5 (cg-RX-API-DMAC7.html) 2025-02-04
JP7869809B2 JP7869809B2 (ja) 2026-06-03

Family

ID=81308304

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561742A Active JP7869809B2 (ja) 2021-04-12 2022-04-11 肥満の治療のためのglp1受容体の活性化因子としての2-((4-((s)-2-(4-クロロ-2-フルオロフェニル)-2-メチルベンゾ[d][1,3]ジオキソール-4-イル)ピペリジン-1-イル)メチル)-1-(((s)-オキセタン-2-イル)メチル)-1h-イミダゾール誘導体

Country Status (4)

Country Link
JP (1) JP7869809B2 (cg-RX-API-DMAC7.html)
CL (1) CL2023003038A1 (cg-RX-API-DMAC7.html)
TW (1) TW202304891A (cg-RX-API-DMAC7.html)
WO (1) WO2022219495A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PE20231181A1 (es) * 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
JP2023538949A (ja) 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
JPWO2023106310A1 (cg-RX-API-DMAC7.html) * 2021-12-07 2023-06-15
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CN119907794A (zh) 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
CR20250178A (es) 2022-11-16 2025-06-06 Lilly Co Eli Agonistas del receptor del péptido-1 similar al glucagón
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
AU2024313246A1 (en) * 2023-06-23 2025-12-11 Novo Nordisk A/S Semaglutide in medical therapy
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
CN122055348A (zh) * 2023-10-19 2026-05-15 伊莱利利公司 取代的苯乙腈及取代的苯乙酸的制备方法
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
AR044399A1 (es) 2003-05-20 2005-09-14 Novartis Ag Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 代謝障害を治療するための組成物および方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
LT3027642T (lt) 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015197446A1 (en) 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
CA3045644C (en) * 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
AU2020256647B2 (en) * 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CA3140972C (en) * 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
PE20231181A1 (es) * 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos

Similar Documents

Publication Publication Date Title
JP2025505198A5 (cg-RX-API-DMAC7.html)
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
RU2469032C2 (ru) Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2018535999A5 (cg-RX-API-DMAC7.html)
JP2014511869A5 (cg-RX-API-DMAC7.html)
JP2006503081A5 (cg-RX-API-DMAC7.html)
JP2017506237A5 (cg-RX-API-DMAC7.html)
RU2016133626A (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
JP2007511485A5 (cg-RX-API-DMAC7.html)
JP2024519487A5 (cg-RX-API-DMAC7.html)
JP2012517479A5 (cg-RX-API-DMAC7.html)
JP2013530240A5 (cg-RX-API-DMAC7.html)
JP2007523181A5 (cg-RX-API-DMAC7.html)
RU98119885A (ru) Фармацевтическая композиция, содержащая соединение, имеющее ангиотензин ii антагонистическую активность
JP2013531070A5 (cg-RX-API-DMAC7.html)
RU2003112610A (ru) Производные пиразола для лечения вирксных заболеваний
JP2011500679A5 (cg-RX-API-DMAC7.html)
JP2022508218A5 (cg-RX-API-DMAC7.html)
RU2010100352A (ru) Соединения пиперидина и их применения
JP2006524686A5 (cg-RX-API-DMAC7.html)
HRP20200606T1 (hr) Derivati fenila kao agonisti kanabinoidnog receptora 2
JP2014523400A5 (cg-RX-API-DMAC7.html)
JP2023547241A5 (cg-RX-API-DMAC7.html)
JP2006507247A5 (cg-RX-API-DMAC7.html)